Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine

Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Stefan Faderl, Susan O'Brien, Amber Fullmer, Jorge E. Cortes, William Wierda, Hagop Kantarjian

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Abstract

Background: Myelodysplastic syndromes (MDS) progress to acute myeloid leukemia (AML) in approximately 30% of patients. Identification of risk factors for progression to AML and overall survival (OS) would help guide treatment decisions. Patients and Methods: We investigated prognostic factors for progression to AML and survival in 163 patients with MDS treated with decitabine 15 mg/m2 over 3 hours every 8 hours for 3 days every 6 weeks (n = 74) or 20 mg/m2 over 1 hour daily for 5 days every 4 weeks (n = 89). Results: Multivariate analysis of pooled baseline data revealed that only study effect was associated with progression to AML. A hemoglobin value at least 10 g/dL, platelet count at least 50 × 103/μL, and lack of chromosome 5 or 7 abnormalities were associated with longer OS. Conclusions: Patients with certain prognostic factors should be considered for other interventions in addition to decitabine treatment.

Original languageEnglish (US)
Pages (from-to)131-138
Number of pages8
JournalClinical Lymphoma, Myeloma and Leukemia
Volume13
Issue number2
DOIs
StatePublished - Apr 2013
Externally publishedYes

Keywords

  • Acute myeloid leukemia
  • Decitabine
  • Myelodysplastic syndromes
  • Myelomonocytic leukemia
  • Risk factors
  • chronic

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Prognostic factors associated with disease progression and overall survival in patients with myelodysplastic syndromes treated with decitabine'. Together they form a unique fingerprint.

Cite this